Biosimilar Antibodies
Affordable, validated biosimilar antibodies for research
240+ functional-grade biosimilar antibodies for in vitro and in vivo experiments — cost-effective alternatives to reference biologics, validated to support drug discovery, molecular biology and cell-based assays.
Why Choose Biosimilar Antibodies?
Reliable, research-grade alternatives to costly reference biologics — validated across the assays you already run.
Cost-effective
A reliable, lower-cost alternative to reference biologics without compromising on performance.
Broadly validated
Tested across ELISA, flow cytometry, Western blotting, biophysical characterization (SPR) and IHC.
Functionally proven
Demonstrated activity in blocking, neutralization, co-stimulation and depletion assays.
Quality-assured
cGMP manufactured with ISO 9001:2015 and ISO 13485:2016 certification, QC’d at every production step.
Shop the Biosimilar Range
Every target comes in three formats — pick the range that matches your experiment.
In Vivo VivoGenie Biosimilars
Fc-mutated, ultra-low-endotoxin biosimilars built for pre-clinical in vivo studies — PK/PD, mechanism-of-action and efficacy testing in animal models.
- 90+ functional-grade biosimilars
- ≥95% purity, ≤1 EU/mg endotoxin
- PD-L1, CTLA-4, HER-2 & 80+ more targets
In Vitro Reference Biosimilars
Nearly identical to the original reference biologic — the standard choice for in vitro assay development and side-by-side comparison studies.
- 100+ reference biosimilars
- ISO 9001:2015 manufactured
- Validated for ELISA, flow cytometry & WB
Detection-Ready Conjugated Biosimilars
Directly labeled with fluorescent dyes or enzymes for fast detection and quantification — no secondary antibody required.
- 100+ conjugated biosimilars
- Biotin, FITC, APC, PE, DyLight®488, HRP
- Ideal for ELISA, flow cytometry, WB, IF & SPR
Browse Biosimilar Antibodies by Target
Search our full catalog of 42+ validated targets — each card links to its biosimilar antibody product page. Browse the full range for 240+ biosimilars.
Need to detect or quantify these biologics?
Our Biosimilar & Therapeutic mAb ELISA Kits measure free drug and anti-drug antibodies (ADA) for 30+ biologics — the perfect companion to your biosimilar antibodies.
How Biosimilar Antibodies Are Made
Assay Genie’s Biosimilar Development Pipeline creates research-grade biosimilars through a rigorous, quality-controlled process — from reference biologic to validated product.
- Select and characterize the reference biologic
- Design and express in optimised host cell lines
- Purify to ≥98% purity with low endotoxin
- Validate structural integrity and function via rigorous QC
Biosimilar Production Pipeline
From reference biologic to validated, research-ready biosimilar in four controlled steps.
Select & characterize
The reference biologic is selected and fully characterized.
Design & express
The biosimilar is designed and expressed in host cell lines.
Purify
Precise purification yields a high-quality, high-purity antibody.
Quality control
Rigorous QC validates structural integrity and functionality.
VivoGenie™ Biosimilars: Product Specifications
Designed to meet the highest quality standards for research and preclinical applications. With exceptional purity (≥95% by SDS-PAGE), VivoGenie biosimilars ensure reliable performance in Western blot, flow cytometry and ELISA assays.
- ≥95% purity, validated by SDS-PAGE
- Low endotoxin (≤1.0 EU/mg)
- ≥95% monomer, verified by SEC
- Sterile PBS (pH 7.2) — no preservatives, stabilizers or carrier proteins
cGMP & ISO Certification
Manufactured in state-of-the-art facilities, our biosimilar antibodies meet the highest standards — current Good Manufacturing Practice (cGMP), ISO 9001:2015 and ISO 13485:2016 — ensuring consistent quality and reliable performance in every batch.
What Researchers Say
“I ordered from Assay Genie for the first time and would like to share my satisfied impression. The article (Bevacizumab; IVMB0232) was used as a positive control and works excellently in Biacore SPR measurements and VEGF bioassay.”
— G. Carsten, Fraunhofer (2024)
Frequently Asked Questions
What are research-grade biosimilars?
Research-grade biosimilars are laboratory-produced proteins designed to mimic the structure and function of approved biologic drugs. They are used in preclinical studies, assay development and other non-clinical applications.
How do research-grade biosimilars differ from therapeutic biosimilars?
Research-grade biosimilars are intended for laboratory and research purposes only. They are not subject to the same regulatory scrutiny as therapeutic biosimilars, which must undergo clinical trials and approval for patient use.
Are research-grade biosimilars the same as reference biologics?
No. Research-grade biosimilars are designed to be similar in structure and function to reference biologics but are not identical. They are primarily used for assay development, drug screening and in vitro/in vivo research.
Are research-grade biosimilars produced using the same expression systems as the original biologics?
They may be produced in similar systems (e.g. CHO cells, E. coli, yeast), but there can be differences in post-translational modifications, glycosylation patterns or impurities.
How is the quality of research-grade biosimilars ensured?
Quality is assessed through purity analysis (SDS-PAGE, HPLC, mass spectrometry), bioactivity assays and binding affinity tests (e.g. ELISA, SPR, BLI).
What are common applications of research-grade biosimilars?
Preclinical drug screening; assay development and validation (ELISA, Western blot, flow cytometry); mechanism of action studies; and comparative studies against reference biologics.
Can research-grade biosimilars be used in animal studies?
Yes — they can be used in in vivo models to study pharmacokinetics, pharmacodynamics and efficacy before moving to clinical-grade biosimilars.
Got a Question?
Tell our PhD-level technical team which target or reference biologic you need, and we’ll help you find the right biosimilar antibody.